Lunai Bioworks expects Nasdaq trading suspension on October 30
LNAI•LNAI•LNAI•LNAI•Lunai Bioworks expects Nasdaq to suspend trading in its common stock on October 30, 2026, after the exchange cited a $9.02 million stockholders’ deficit and failure to meet its $2.5 million equity requirement. The company will not seek a hearing and expects voluntary delisting around November 12.
Lunai Bioworks’ Nasdaq-listed common stock is expected to be suspended from trading at the opening of business on October 30, 2026. Nasdaq’s October 21 delisting determination cited noncompliance with its $2.5 million minimum stockholders’ equity requirement; the company reported a $9.02 million stockholders’ deficit for the fiscal year ended June 30, 2026.
The company will not seek a hearing, and voluntary delisting is expected to take effect on or about November 12, 2026. Lunai Bioworks does not plan to arrange over-the-counter quotation, leaving the common stock without an assured trading market following the suspension.
